Grown Rogue International (GRUSF) Capital Expenditures (2018 - 2026)
Grown Rogue International's (GRUSF) quarterly Capital Expenditures came in at $2.5 million in Q1 2026, up 942.27% year-on-year from $241532.0 in Q1 2025, and down 100.0% quarter-over-quarter from $1056.5 billion in Q4 2025.
Grown Rogue International (GRUSF) Capital Expenditures (2018 - 2026) Analysis & Trends
Grown Rogue International's Capital Expenditures history runs 9 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 942.27% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 50.07% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, up 14.13% from the prior year.
- Capital Expenditures declined to $2.5 million in Q1 2026 per GRUSF's latest filing, from $1056.5 billion in the prior quarter.
- Across five years, Capital Expenditures topped out at $1267.5 billion in Q4 2024 and bottomed at -$1267.5 billion in Q3 2024.
- The 5-year median for Capital Expenditures is -$297314.0 (2024), against an average of $548372.8.
- Across the five-year window, Capital Expenditures slumped 261.34% in 2022 and jumped 1000503556.29% in 2024, its largest moves.
- Year by year, Capital Expenditures stood at -$574595.0 in 2022, then surged by 122.05% to $126690.0 in 2023, then soared by 1000503556.29% to $1267.5 billion in 2024, then declined by 16.65% to $1056.5 billion in 2025, then tumbled by 100.0% to $2.5 million in 2026.
- Per Business Quant, the three latest GRUSF Capital Expenditures figures stand at $2.5 million (Q1 2026), $1056.5 billion (Q4 2025), and -$1056.5 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 2.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.52 Mn |
| Mar 31, 2026 | 2.52 Mn |
| Dec 31, 2025 | 1,056.50 Bn |
| Dec 31, 2025 | 1,056.50 Bn |
| Sep 30, 2025 | -1,056.50 Bn |
| Sep 30, 2025 | -1,056.50 Bn |
| Jun 30, 2025 | -773,726.00 |
| Jun 30, 2025 | -773,726.00 |
| Mar 31, 2025 | 241,532.00 |
| Mar 31, 2025 | 241,532.00 |
| Dec 31, 2024 | 1,267.54 Bn |
| Dec 31, 2024 | 1,267.54 Bn |
| Sep 30, 2024 | -1,267.53 Bn |
| Sep 30, 2024 | -1,267.53 Bn |
| Jun 30, 2024 | -230,497.00 |
| Jun 30, 2024 | -230,497.00 |
| Mar 31, 2024 | -297,314.00 |
| Mar 31, 2024 | -297,314.00 |
| Dec 31, 2023 | 126,690.00 |
| Dec 31, 2023 | 126,690.00 |